Overexpression of PTEN as a negative regulator of PI3K/AKT and downregulation of β-catenin expression by inhibiting AlOX15 expression can increase susceptibility of CML LSCs to TKI therapy and delayed disease progression [105]. The gene discussed is ALOX15; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.